2 mg tirzepatide Mounjaro (tirzepatide) for the Treatment of Type Diabetes, USA Tirzepatide vs. Semaglutide for Weight

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now considered the first choice of injectable therapy for many people with T2D, with several members of the class having proven cardiovascular efficacy 3

Stracquadanio, M., Ciotta, L., & Palumbo, M

TRULICITY is not for use in people with type 1 diabetes and is not recommended for use in people with severe stomach or intestinal problems

Medication optimization strategies include following the FDA-approved titration schedule, which allows gradual adaptation to increasing doses

(3) Gaining more confidence in your appearance supports mental and emotional health, causing a chain reaction of overall positivity in your life

Common side effects include gastrointestinal symptoms such as nausea, diarrhoea, vomiting, and constipation